Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB87137
CAS No:1159490-85-3
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $9.45 | Total: $945.00 |
1 | 50 | $10.92 | Total: $546.00 |
1 | 25 | $12.81 | Total: $320.25 |
1 | 10 | $15.12 | Total: $151.20 |
1 | 5 | $17.85 | Total: $89.25 |
Molecular Formula | C19H16N8O |
Molecular Weight | 372.38 |
CAS Numbers | 1159490-85-3 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO and Water |
Purity | 99% (HPLC) |
Synonym | PF04217903; PF 04217903; PF-04217903; PF4217903; PF-4217903; PF 4217903. |
IUPAC/Chemical Name | 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol |
InChl Key | PDMUGYOXRHVNMO-UHFFFAOYSA-N |
InChl Code | InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2 |
SMILES Code | OCCN1N=CC(C2=CN=C3C(N(CC4=CC=C5N=CC=CC5=C4)N=N3)=N2)=C1 |
References | 1) Yan L, et al., Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations. J Biomol Struct Dyn. 2017 Jun 20:1-17. doi: 10.1080/07391102.2017.1340852. [Epub ahead of print] PubMed PMID: 28599617. 2) Yu LL, Liu YJ, Wang ZH, Shi L, Liu LX. The study of endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms. Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):795-803. Retraction in: Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1176. PubMed PMID: 28272703. |
A potent, selective, orally bioavailable c-Met kinase inhibitor